Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
- 2025-04
-
There were limitations to this study Specifically although r
2022-03-31
There were limitations to this study. Specifically, although rigorously examined for accuracy, the NCDB and SEER databases still suffer from issues with data entry and completeness of the treatment record. Of note, although the data were collected on a modern cohort of patients treated from 2010 to
-
It is extremely difficult to predict a
2022-03-31
It is extremely difficult to predict a plausible conformer of hsGCαβ heterodimer with right orientation of multiple domains. Even though the template identities in case of dimeric domains were not high enough but still we modelled the entire heterodimeric structure of hsGCαβ with a reasonable and ju
-
br FFA GPR was deorphanised as the second receptor for
2022-03-31
FFA4 GPR120 was deorphanised as the second receptor for long-chain fatty acids in 2005 [5]. Initial focus highlighted expression in the lower gut, the capacity of unsaturated fatty acids to promote release of the incretin glucagon-like peptide-1 (GLP-1) from the enteroendocrine cell line STC-1, a
-
Experiments conducted on the human parasite Leishmania major
2022-03-31
Experiments conducted on the human parasite Leishmania major has shown that specific parasitic antigens are involved in steering the immune responses to “protective” as opposed to “disease” state (Reiner et al., 1993; Reiner and Locksley, 1995; and Sjölander et al., 1998) and that antigenic composit
-
The occurrence of MDR in cancer patients undergoing chemothe
2022-03-31
The occurrence of MDR in cancer patients undergoing chemotherapy can be mimicked in the laboratory by culturing cancer AF 12198 mg in the presence of chemotherapeutic drugs, thereby enforcing the evolution of acquired drug resistance. This has been described in multiple model systems including the
-
Studies dealing with the effects of ischemia on
2022-03-31
Studies dealing with the effects of ischemia on EAATs have been previously reported, but some discrepancies in literature appear between them probably as a consequence of the different models, species, time of reperfusion after ischemia and age of the animals. Thus, in human, Cy5.5 NHS ester stroke
-
Previous studies have suggested that GPR protects from bone
2022-03-31
Previous studies have suggested that GPR40 protects from bone loss via inhibition of osteoclasts. Wittrant et al. used GPR40 knock-out mice and primary osteoclasts to investigate the role of GPR40 on bone remodelling. Their results in primary osteoclast cultures and the RAW264.7 cell line showed tha
-
Next we investigated the transfer of peptides
2022-03-30
Next, we investigated the transfer of peptides and proteins between contacting cells by nano-LC-MS/MS analysis using the fractions corresponding to molecules higher than 3 kDa. The MS data analysis revealed the direct transfer of several labelled peptides between receivers and donors. Labelled pepti
-
The present study also demonstrated that edoxaban
2022-03-30
The present study also demonstrated that edoxaban inhibited both free and clot-bound FXa activity. The IC50 values for free and clot-bound FXa in this study are well consistent with Ki values for free FXa and FXa incorporated in prothrombinase complex (0.561 and 2.98nM, respectively) in our previous
-
In conclusion a series of new
2022-03-30
In conclusion, a series of new 3-carboxamido-5-aryl-isoxazoles was designed, synthesized and screened for their inhibitory potency against FAAH. Their cytotoxicity was determined and their lipophilicity was calculated. Compounds bearing a 3-substituted biphenyl moiety with high Log values displayed
-
hydroxychloroquine sulfate br Introduction Erythropoietin EP
2022-03-30
Introduction Erythropoietin (EPO) is a glycoprotein hormone and the principal stimulator of erythropoiesis (Jelkmann, 2011). EPO promotes the proliferation and differentiation of red blood cells, which is important for oxygen transport. Low EPO levels in blood cause anemia; however, excessive lev
-
The inhibition of HDAC increases the level of histone
2022-03-30
The inhibition of HDAC increases the level of histone acetylation and consequently turns the chromatin to be loose and active, allowing multiple transcription factors to access to promoters of diverse genes including tumor suppressor genes []. As compound possessed potent HDAC inhibitory activity a
-
br Hydroxamic acids br Inhibitors with
2022-03-30
Hydroxamic acids Inhibitors with reporting modalities Dual or more HDAC inhibitors Conclusion Finally, non-human HDAC such as Schistosoma mansoni HDAC8 are targeted for parasitic diseases and recent work highlight the interest of HDACs in viral infections. Despite their discovery in the
-
Reduction of the hydrolysis of ATP is an
2022-03-30
Reduction of the hydrolysis of ATP is an important strategy to reduce ischemia/reperfusion injury. Increased intracellular concentrations of solutes secondary to ATP depletion are known to result in osmotic swelling that may be sufficient to cause sarcolemmal rupture. Cinaciguat activates sGC direct
-
Pharmacologic approaches of inhibiting GSNOR activity have r
2022-03-29
Pharmacologic approaches of inhibiting GSNOR activity have reached the point of clinical development with the recent announcement of the first cystic fibrosis patients treated with the first-in-class GSNOR inhibitor, N6022 (N30 Pharmaceuticals). Clinical development is ongoing for other indications
15689 records 437/1046 page Previous Next First page 上5页 436437438439440 下5页 Last page